Metronidazole and Baclofen Kits Enable Safe, Easy and Compliant Preparation by Pharmacists
WILMINGTON, Mass. (October 3, 2016) – CutisPharma, a specialty pharmaceutical company that develops and distributes kits used by pharmacists to safely create compounded medications, has expanded its product portfolio to include FIRST® Unit-of-Use Prescription Compounding Kits for Metronidazole and Baclofen oral suspensions, two medications that pharmacists are often called upon to compound for young and elderly patients who have difficulty using commercially available versions of the drug.
“While our company continues to grow and evolve into a full-scale, high-quality specialty pharmaceutical company, there remains significant pharmacist demand for our compounding kits because of their convenience, consistency and facilitation of pharmacist compliance with compounding regulations,” said Kevin Campbell, Vice President, Sales and Marketing of CutisPharma. “Many small children and senior citizens require a suspension in order to use these medications, and we offer a safe and reliable product easily prepared by a pharmacist.”
FIRST® – Metronidazole allows pharmacists to prepare a grape-flavored suspension in either 50mg/mL or 100mg/mL strengths for patients needing an oral suspension formulation of this therapy.
FIRST® – Baclofen enables the preparation of a grape-flavored suspension in 1 and 5 mg/mL strengths.
The kits each have pre-measured powder and diluent that the pharmacist combines into a suspension, negating the need for any weighing, measuring or stirring. The kits, manufactured in an FDA-registered, cGMP pharmaceutical facility, facilitate pharmacist compliance with Section 503A of the Food, Drug, and Cosmetic Act and USP <795> standards governing pharmacy compounding.
With these new product additions, CutisPharma now produces 29 kits, which are carried by all major retail chain pharmacies, leading hospitals and long term care facilities, and independent pharmacies.
About CutisPharma
CutisPharma, Inc., based in Wilmington, Mass., is a privately held, specialty pharmaceutical company that has been an innovation leader in the pharmaceutical compounding market, developing kits used by pharmacists to safely create compounded medications. Building on the strength of its FIRST® Unit-of-Use kit portfolio, the company has expanded its focus toward developing and commercializing FDA-approved drugs in niche markets of high-unmet need. For more information, visit www.cutispharma.com.
Contact:
Greg Turner, Ball Consulting Group, LLC
Phone: 617-243-9950
Email: greg@ballcg.com
